Browse
related articles
UAE physicians gather to discuss latest healthcare advances
- United Arab Emirates: Thursday, October 06 - 2005 at 11:21
- PRESS RELEASE
Two of the UAE's leading experts on gastroenterology have come together to host a major congress for physicians, aiming to share the latest modern methods for controlling bowel disorders.
The aim of the event is to deepen understanding, share some of the clinical practices and advances which have been made in recent years in reducing the symptoms, and combat the advance of these serious conditions.
"Modern medicine has taken significant steps forward in helping to reduce the symptoms associated with irritable bowel syndrome and chronic constipation, and addressing their underlying causes," said Dr. Asa'd Dajani, who runs his own clinic in Sharjah which concentrates on bowel and stomach disorders.
"We must also look at how we can promote understanding of bowel conditions; too many patients still don't understand what it is and that help is out there. Too many sufferers aren't aware of the vast ways and means there are to counter the painful symptoms," said Dr. Adnan Abu Hammour, former chairman of the Department of Medicine at the American Hospital, Dubai, and now moving to a private practice in Jumeirah.
IBS is a distressing condition that is thought to afflict around 10 to 15 per cent of the UAE's adult population, the majority of them women with symptoms including abdominal pain, bloating, constipation or diarrhea.
Although the exact cause is unknown, the condition is thought to be caused by a combination of factors including abnormal movements of the intestine and altered sensation of the gut; some people develop IBS following gut infections and food poisoning.
One of the areas of discussion at the meeting was the different drugs on the market designed to counter stomach and bowel problems. Since its introduction, one such drug, Zelmac, has received significant positive feedback from physicians for helping female sufferers of IBS across the GCC.
Also consider reading:
Browse
related articles
- » Nakheel commences handover of Marina Residences
- » Alba appoints new Chief Executive
- » Alcatel-Lucent shares four critical determinants for FTTx implementation at FTTH Middle East Conference
- » World tallest hotel, the Rose Rayhaan by Rotana, to open in Dubai
- » DAE delivers second Boeing 737-800 NG to Garuda
Notes and media contacts
About NovartisNovartis AG (NYSE: NVS) is a world leader in pharmaceuticals and consumer health. Our primary goal is to develop and market new and more effective ways to treat patients - in essence, to bring our vision of research to life. In 2004, the Group invested approximately USD 4.2 billion in R&D. Headquartered in Basel, Switzerland; Novartis Group companies employ about 81,400 people and operate in over 140 countries around the world.
Disclaimer:
Articles in this section are primarily provided directly by the companies appearing or PR agencies which are solely responsible for the content. The companies concerned may use the above content on their respective web sites provided they link back to http://www.ameinfo.com
Any opinions, advice, statements, offers or other information expressed in this section of the AMEinfo.com Web site are those of the authors and do not necessarily reflect the views of AME Info FZ LLC / Emap Limited. AME Info FZ LLC / Emap Limited is not responsible or liable for the content, accuracy or reliability of any material, advice, opinion or statement in this section of the AMEinfo.com Web site.
For details about submitting your stories, please read the guide - all content published is subject to our terms and conditions
Posted by Anne-Birte Stensgaard, Senior News Editor
